What is the appropriate colchicine dosing regimen for an adult with acute pericarditis, including adjustments for weight, renal or hepatic impairment, age over 65, and drug interactions?

Colchicine Dosing for Pericarditis

For acute pericarditis, administer colchicine 0.5 mg twice daily for patients ≥70 kg or 0.5 mg once daily for patients <70 kg, continued for 3 months as adjunct to NSAIDs or aspirin. 1

Standard Dosing Algorithm

Acute Pericarditis (First Episode)

• Weight ≥70 kg: 0.5 mg twice daily for 3 months 1
• Weight <70 kg: 0.5 mg once daily for 3 months 1
• No loading dose is recommended 1
• Always combine with NSAIDs (ibuprofen 600 mg every 8 hours or aspirin 750-1000 mg every 8 hours) 1

The 2015 ESC Guidelines provide Class I, Level A evidence supporting colchicine as first-line therapy alongside NSAIDs, demonstrating significant reduction in recurrence rates from 37.5% to 16.7% 2. This represents a number needed to treat of only 4 patients to prevent one recurrence.

Recurrent Pericarditis

• Weight ≥70 kg: 0.5 mg twice daily for ≥6 months 1
• Weight <70 kg: 0.5 mg once daily for ≥6 months 1
• Duration extended to at least 6 months due to higher recurrence risk 1

Tapering Strategy

Tapering is not mandatory but may be considered in the final weeks 1:

• Weight <70 kg: Reduce to 0.5 mg every other day 1
• Weight ≥70 kg: Reduce to 0.5 mg once daily 1

Dose Adjustments for Renal Impairment

Mild Renal Impairment (CrCl 50-80 mL/min)

• No dose adjustment required 3
• Monitor closely for adverse effects 3

Moderate Renal Impairment (CrCl 30-50 mL/min)

• No dose adjustment required 3
• Close monitoring mandatory for colchicine toxicity 3

Severe Renal Impairment (CrCl <30 mL/min)

• Start with 0.3 mg once daily 3
• Any dose increase requires close monitoring 3
• Consider 0.48 mg daily if oral solution available for more precise dosing 4

Dialysis Patients

• 0.3 mg twice weekly for prophylaxis 3
• Avoid repeated treatment courses 3

Critical pitfall: The FDA label 3 does not recommend treating acute gout flares (and by extension, acute inflammatory conditions) in patients on dialysis with standard doses—use extreme caution and reduced dosing.

Dose Adjustments for Hepatic Impairment

The FDA label 3 states that patients with both renal AND hepatic impairment should not receive colchicine when taking strong CYP3A4 or P-gp inhibitors. For isolated hepatic impairment without drug interactions:

• Monitor closely for toxicity
• Consider dose reduction similar to moderate renal impairment
• No specific dosing guidelines exist, requiring clinical judgment

Drug Interaction Adjustments

Strong CYP3A4 Inhibitors (Clarithromycin, Ketoconazole, Ritonavir, etc.)

Do not use colchicine in patients with renal or hepatic impairment taking these agents 3

For patients with normal organ function:

• Reduce to 0.3 mg once daily (from 0.6 mg twice daily) 3
• Maximum 0.6 mg daily (may give as 0.3 mg twice daily) 3

Moderate CYP3A4 Inhibitors (Diltiazem, Verapamil, Erythromycin, Fluconazole, Grapefruit Juice)

• Reduce to 0.3 mg twice daily OR 0.6 mg once daily (from 0.6 mg twice daily) 3
• Maximum 1.2 mg daily 3
• Neuromuscular toxicity specifically reported with diltiazem and verapamil 3

P-glycoprotein Inhibitors (Cyclosporine, Ranolazine)

• Reduce to 0.3 mg once daily (from 0.6 mg twice daily) 3
• Fatal toxicity reported with cyclosporine 3
• Maximum 0.6 mg daily 3

CYP3A4 Inducers (Carbamazepine, Phenytoin, Rifampin)

• May render colchicine ineffective by reducing plasma levels 5
• Consider therapeutic drug monitoring if available
• May require dose increase, though specific recommendations lacking
• Monitor for treatment failure (persistent symptoms, elevated CRP)

Age-Related Considerations

Patients >65 Years

The guidelines [1-1] do not specify age-based dose reductions beyond the weight-based algorithm. However:

• Age-related decline in renal function is common—calculate CrCl using Cockcroft-Gault equation 3
• For women: CrCl = [140-age × weight(kg)] / [72 × SCr(mg/dL)] × 0.85 3
• For men: CrCl = [140-age × weight(kg)] / [72 × SCr(mg/dL)] 3
• Apply renal dosing adjustments based on calculated clearance
• Elderly patients more susceptible to drug interactions—review medication list carefully

Safety Monitoring

Common side effects (5-10% of patients): Gastrointestinal intolerance (diarrhea, nausea, abdominal pain) 6

• Managed by temporary dose reduction or brief discontinuation 6
• Rarely requires permanent cessation 2

Serious toxicity indicators:

• Neuromuscular symptoms (weakness, elevated CK)
• Bone marrow suppression (cytopenias)
• Rhabdomyolysis

Monitoring strategy:

• Baseline: CBC, CMP, CK
• Follow CRP levels to guide treatment duration 1
• Reassess renal function if clinical status changes
• Review for new drug interactions at each visit

Clinical Pearls

Colchicine significantly reduces recurrence risk from 50% after first recurrence to approximately 25% when used appropriately 1. The drug concentrates in white blood cells and interferes with microtubule polymerization, providing anti-inflammatory effects beyond simple NSAID therapy 6.

Never use corticosteroids as first-line therapy—they increase recurrence rates and promote drug dependence 1. Reserve steroids only for NSAID/colchicine contraindications or failure 1.

Treatment duration matters: 3 months for first episode, ≥6 months for recurrent disease [1-1]. Premature discontinuation increases recurrence risk.

The narrow therapeutic index of colchicine (therapeutic range 0.5-3 ng/mL) 4, 7 demands careful attention to renal function, drug interactions, and patient weight. When in doubt about complex interactions, err on the side of dose reduction rather than standard dosing.